BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Toth K, Wold WS. Increasing the efficacy of oncolytic adenovirus vectors. Viruses 2010;2:1844-66. [PMID: 21994711 DOI: 10.3390/v2091844] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Chai D, Qiu D, Zhang Z, Yuchen Shi S, Wang G, Fang L, Li H, Li H, Tian H, Zheng J. Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer. J Cell Mol Med 2020;24:10744-55. [PMID: 32725966 DOI: 10.1111/jcmm.15697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Uehara N, Otsuki N, Kubo M, Kitamoto J, Kojima Y, Teshima M, Shinomiya H, Shirakawa T, Nibu KI. Oncolytic effect of Midkine promoter-based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891. Cancer Rep (Hoboken) 2020;3:e1231. [PMID: 32671980 DOI: 10.1002/cnr2.1231] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol 2020;13:84. [PMID: 32600470 DOI: 10.1186/s13045-020-00922-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 52] [Article Influence: 11.5] [Reference Citation Analysis]
4 Yan Y, Jing S, Feng L, Zhang J, Zeng Z, Li M, Zhao S, Ou J, Lan W, Guan W, Wu X, Wu J, Seto D, Zhang Q. Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: "Adenovirus Vaccine Within an Adenovirus Vector". Virol Sin 2021;36:354-64. [PMID: 32458297 DOI: 10.1007/s12250-020-00234-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Miao J, Chard LS, Wang Z, Wang Y. Syrian Hamster as an Animal Model for the Study on Infectious Diseases. Front Immunol 2019;10:2329. [PMID: 31632404 DOI: 10.3389/fimmu.2019.02329] [Cited by in Crossref: 23] [Cited by in F6Publishing: 33] [Article Influence: 7.7] [Reference Citation Analysis]
6 Hong J, Yun CO. Overcoming the limitations of locally administered oncolytic virotherapy. BMC Biomed Eng 2019;1:17. [PMID: 32903299 DOI: 10.1186/s42490-019-0016-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
7 Stepanenko AA, Chekhonin VP. A compendium of adenovirus genetic modifications for enhanced replication, oncolysis, and tumor immunosurveillance in cancer therapy. Gene 2018;679:11-8. [PMID: 30171937 DOI: 10.1016/j.gene.2018.08.069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
8 Stepanenko AA, Chekhonin VP. Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX. Virus Res 2018;257:40-51. [PMID: 30125593 DOI: 10.1016/j.virusres.2018.08.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
9 Yang C, Zhang J, Ding M, Xu K, Li L, Mao L, Zheng J. Ki67 targeted strategies for cancer therapy. Clin Transl Oncol 2018;20:570-5. [DOI: 10.1007/s12094-017-1774-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 89] [Article Influence: 11.4] [Reference Citation Analysis]
10 Fu YR, Turnell AS, Davis S, Heesom KJ, Evans VC, Matthews DA. Comparison of protein expression during wild-type, and E1B-55k-deletion, adenovirus infection using quantitative time-course proteomics. J Gen Virol 2017;98:1377-88. [PMID: 28631589 DOI: 10.1099/jgv.0.000781] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ma J, Li N, Zhao J, Lu J, Ma Y, Zhu Q, Dong Z, Liu K, Ming L. Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo. Oncol Lett 2017;13:4868-74. [PMID: 28599488 DOI: 10.3892/ol.2017.6069] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
12 Yura Y, Hamada M. Development of oncolytic virotherapy for the treatment of oral cancer – At the waiting stage for clinical use. Oral Science International 2017;14:1-12. [DOI: 10.1016/s1348-8643(16)30016-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
13 Jung BK, Lee YK, Hong J, Ghandehari H, Yun CO. Mild Hyperthermia Induced by Gold Nanorod-Mediated Plasmonic Photothermal Therapy Enhances Transduction and Replication of Oncolytic Adenoviral Gene Delivery. ACS Nano 2016;10:10533-43. [PMID: 27805805 DOI: 10.1021/acsnano.6b06530] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 11.8] [Reference Citation Analysis]
14 Kim JW, Auffinger B, Spencer DA, Miska J, Chang AL, Kane JR, Young JS, Kanojia D, Qiao J, Mann JF, Zhang L, Wu M, Ahmed AU, Aboody KS, Strong TV, Hébert CD, Lesniak MS. Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters. J Transl Med 2016;14:134. [PMID: 27184224 DOI: 10.1186/s12967-016-0895-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
15 Li Y, Li YF, Si CZ, Zhu YH, Jin Y, Zhu TT, Liu MY, Liu GY. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells. Virus Res 2016;220:172-8. [PMID: 27157859 DOI: 10.1016/j.virusres.2016.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
16 Appaiahgari MB, Vrati S. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opinion on Biological Therapy 2015;15:337-51. [DOI: 10.1517/14712598.2015.993374] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
17 Prasad V, Suomalainen M, Pennauer M, Yakimovich A, Andriasyan V, Hemmi S, Greber UF. Chemical induction of unfolded protein response enhances cancer cell killing through lytic virus infection. J Virol 2014;88:13086-98. [PMID: 25187554 DOI: 10.1128/JVI.02156-14] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
18 Jung S, Choi J, Yun C, Yhee JY, Price R, Kim SH, Kwon IC, Ghandehari H. Sustained local delivery of oncolytic short hairpin RNA adenoviruses for treatment of head and neck cancer: Sustained local delivery of oncolytic shRNA adenoviruses. J Gene Med 2014;16:143-52. [DOI: 10.1002/jgm.2770] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ghebremedhin B. Human adenovirus: Viral pathogen with increasing importance. Eur J Microbiol Immunol (Bp) 2014;4:26-33. [PMID: 24678403 DOI: 10.1556/EuJMI.4.2014.1.2] [Cited by in Crossref: 150] [Cited by in F6Publishing: 144] [Article Influence: 18.8] [Reference Citation Analysis]
20 Young BA, Spencer JF, Ying B, Toth K, Wold WS. The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model. Cancer Gene Ther 2013;20:531-7. [PMID: 23928730 DOI: 10.1038/cgt.2013.50] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
21 Young BA, Spencer JF, Ying B, Tollefson AE, Toth K, Wold WS. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. Cancer Gene Ther 2013;20:521-30. [PMID: 23928731 DOI: 10.1038/cgt.2013.49] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
22 Lu ZZ, Zou XH, Lastinger K, Williams A, Qu JG, Estes DM. Enhanced growth of recombinant human adenovirus type 41 (HAdV-41) carrying ADP gene. Virus Res 2013;176:61-8. [PMID: 23769974 DOI: 10.1016/j.virusres.2013.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
23 Koski A, Karli E, Kipar A, Escutenaire S, Kanerva A, Hemminki A. Mutation of the fiber shaft heparan sulphate binding site of a 5/3 chimeric adenovirus reduces liver tropism. PLoS One 2013;8:e60032. [PMID: 23585829 DOI: 10.1371/journal.pone.0060032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
24 Wold WS, Toth K. Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv Cancer Res 2012;115:69-92. [PMID: 23021242 DOI: 10.1016/B978-0-12-398342-8.00003-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
25 Liu J, Fang L, Cheng Q, Li L, Su C, Zhang B, Pei D, Yang J, Li W, Zheng J. Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell. Cancer Sci 2012;103:1880-8. [PMID: 22775978 DOI: 10.1111/j.1349-7006.2012.02380.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
26 Svyatchenko VA, Tarasova MV, Netesov SV, Chumakov PM. Oncolytic adenoviruses in anticancer therapy: Current status and prospects. Mol Biol 2012;46:496-507. [DOI: 10.1134/s0026893312040103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
27 Li S, Tong J, Rahman MM, Shepherd TG, McFadden G. Oncolytic virotherapy for ovarian cancer. Oncolytic Virother 2012;1:1-21. [PMID: 25977900 DOI: 10.2147/ov.s31626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
28 Seo J, Yun CO, Kwon OJ, Choi EJ, Song JY, Choi I, Cho KH. A proteoliposome containing apolipoprotein A-I mutant (V156K) enhances rapid tumor regression activity of human origin oncolytic adenovirus in tumor-bearing zebrafish and mice. Mol Cells 2012;34:143-8. [PMID: 22851220 DOI: 10.1007/s10059-012-2291-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
29 Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M, Ali A. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 2012;18:771-81. [PMID: 22714538 DOI: 10.1007/s12253-012-9548-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
30 Rojas JJ, Thorne SH. Theranostic potential of oncolytic vaccinia virus. Theranostics 2012;2:363-73. [PMID: 22509200 DOI: 10.7150/thno.3724] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]